Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders. Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to deliver life-changing brain health medicines. The company is committed to ...